Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.